PsychoGenics
PsychoGenics Inc. and its discovery arm, PGI Drug Discovery LLC (collectively known as PsychoGenics), have pioneered the translation of rodent behavioral and physiological responses into robust, high-throughput and high-content phenotyping. PsychoGenics' drug discovery platforms, SmartCube®, NeuroCube®, PhenoCube®, and eCube™ have been used in shared-risk partnerships with major pharma companies including Sunovion, Roche, and Karuna, resulting in the discovery of several novel compounds now in clinical trials or advanced preclinical development. PsychoGenics' capabilities also include standard behavioral testing, electrophysiology, translational EEG, molecular biology, microdialysis, and quantitative immunohistochemistry. In addition, the company offers a variety of in-licensed transgenic mouse models that support research in areas such as Huntington's disease, autism spectrum disorders, psychosis/schizophrenia, depression, PTSD, Alzheimer's disease, Parkinson's disease, muscular dystrophy, ALS, and seizure disorders.
About PsychoGenics
Founded
1999Estimated Revenue
$10M-$50MEmployees
51-250Funding / Mkt. Cap
$1MCategory
Industry
ResearchLocation
City
ParamusState
New JerseyCountry
United StatesTech Stack (76)
IT Security
Devops And Development
Collaboration
Communications
Platform And Storage
Customer Management
Business Intelligence And Analytics
Sales
E-commerce
Productivity And Operations
IT Management
Widgets
WP Rocket
HubSpot WordPress Plugin
Slack
Sitelinks Search Box
Wordpress Plugins
Font Awesome
Google Font API
Google Tag Manager
Moove GDPR Cookie Compliance
Yoast Plugins
GDPR Cookie Compliance
SVG Support
Max Mega Menu
PDFjs Viewer for Wordpress
Video PopUp for Wordpress
US Privacy User Signal Mechanism
CrUX Dataset
Global Privacy Control